LONSURF® get NHI reimbursement for metastatic colorectal cancer treatment since Dec/01/2018.

2018.11.162018.11.16 最新消息最新消息

TTY Biopharm’s oncology drug LONSURF® get reimbursement from National Health Insurance Administration since Dec/01/2018. More than 2,000 metastatic colorectal cancer patients/ year will be potentially able to receive LONSURF® treatment after reimbursement.


TTY Biopharm (4105.TWO) continues its commitment to strengthen oncology business with continuous investments in developing new drugs and optimizing product portfolio for decades. TTY Biopharm signed an agreement with Taiho Pharmaceutical Co., Ltd. (Japan) in 2016 to receive an exclusive license to present registration dossier, to develop new indication and to sell LONSURF® in Taiwan and got license approval from Taiwan Food and Drug Administrationthis January, and finally got NHI reimbursement from Dec/01/2018.


For the past decade, colorectal cancer is the most common cancer in Taiwan. But the 5-year survival rate of metastatic colorectal cancer is merely 12%. There are emergency clinical unmet needs for new drug development. LONSURF® is an oral anticancer drug, comprising the combination of trifluridine (FTD) and tipiracil (TPI), whose dual mechanism of action is designed to maintain clinical activity and differs from fluoropyrimidines. It already launched in Japan (2014); US (2015) and EU (2016). The reimbursement criteria is as Indication for metastatic colorectal cancer patients who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. The patients need to acquire pre-approval of a cycle of 8 weeks treatment.


TTY Biopharm endeavors to specialize in the anti-cancer area and develop special drug formulations, especially well-known liposome products and other special delivery systems. Through building global partnerships and collaboration agreements, this new agreement of licensing in new oral oncology drug accelerates the completion of TTY Biopharm’s product portfolio, and also strengthens its technology platform to cure cancer related diseases, and brings more benefits to patients.


<About Taiho Pharmaceutical Co., Ltd.> Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd. (https://www.otsuka.com/en/), is an R&D-driven specialty pharma focusing on the three fields of oncology, allergy and immunology, and urology. Its corporate philosophy takes the form of a pledge: “We strive to improve human health and contribute to a society enriched by smiles.” In the field of oncology in particular, Taiho Pharmaceutical is known as a leading company in Japan for developing innovative medicines for the treatment of cancer, a reputation that is rapidly expanding through their extensive global R&D efforts. In areas other than oncology as well, the company creates and markets quality products that effectively treat medical conditions and can help improve people’s quality of life. Always putting customers first, Taiho Pharmaceutical also aims to offer consumer healthcare products that support people’s efforts to lead fulfilling and rewarding lives. For more information about Taiho Pharmaceutical, please visit https://www.taiho.co.jp/en.


<About TTY Biopharm Co., Ltd.> TTY Biopharm Co., Ltd. (TWO: 4105), is a leading large-scale company which develops new medical entities, including innovative therapeutic modalities to fulfill unmet medical needs and devotes to R&D and manufacture on specialty products in drug delivery systems, i.e., liposome and microsphere technology. TTY is well-known for its continuous self-innovation and accumulated knowledge, technology and networked relationships from 1960. Globally, TTY has led in super-generic drugs and special formulations and had dealer distribution networks around the world and three main Asian subsidiaries in Vietnam, Philippines and Thailand; in Taiwan, TTY has ranked in top 1% of largest biopharmaceutical companies in oncology and critical infection fields. TTY has succeeded in penetrating its own R&D products into international regions and has become the best partner with global companies. TTY is not satisfied with triumphing in Taiwan and certain Asian markets only. In the future, based on its expertise in Asian markets, TTY will continue to strengthen its position in international markets through developing high-barriers and prove of concept new drugs and bio-drugs with innovative formulations. TTY’s collaboration and investments in developing drugs and innovative agents of novel ingredients will be expected. A long-term and sustainable growth will be thrived.


TOP